A multicenter open-label phase I/II study to assess the safety, tolerability, and efficacy of three dose levels of TuNEX in patients with rheumatoid arthritis

被引:4
|
作者
Chen, Der-Yuan [1 ,2 ,3 ]
Lai, Ning-Sheng [4 ,5 ]
Lu, Ling-Ying [6 ]
Chou, Hsiu-Cheng [1 ]
Chen, Yi-Hsing [1 ,2 ]
Hsieh, Tsu-Yi [1 ,3 ]
Chen, Yi-Ming [1 ,2 ]
Lan, Joung-Liang [1 ,2 ,3 ]
机构
[1] Taichung Vet Gen Hosp, Div Allergy Immunol & Rheumatol, Taichung 407, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Fac Med, Taipei 112, Taiwan
[3] Chung Shan Med Univ, Sch Med, Taichung, Taiwan
[4] Buddhist Dalin Tzu Chi Hosp, Div Allergy Immunol & Rheumatol, Chiayi, Taiwan
[5] Tzu Chi Univ, Coll Med, Hualien, Taiwan
[6] Kaohsiung Vet Gen Hosp, Div Allergy Immunol & Rheumatol, Kaohsiung, Taiwan
关键词
efficacy; immunology; RA; rheumatoid arthritis; TNF-alpha; tumor necrosis factor; TuNEX; HEALTH-ASSESSMENT QUESTIONNAIRE; COLLEGE-OF-RHEUMATOLOGY; DOUBLE-BLIND; TAIWANESE PATIENTS; ETANERCEPT; METHOTREXATE; IMPROVEMENT; ASSOCIATION; VALIDATION; CYTOKINES;
D O I
10.1016/j.jcma.2011.10.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Tumor necrosis factor (TNF)-alpha is a pivotal inflammatory cytokine in the pathogenesis of rheumatoid arthritis (RA). TuNEX, a recombinant TNE-alpha receptor protein, can effectively bind TNF-alpha. The purpose of this phase I/III dose-escalation study was to assess the safety and preliminary efficacy of three dose levels of TuNEX in Taiwanese patients with RA. Methods: Eighteen patients with active RA from three medical centers who had failed previous therapy with at least one disease modifying antirheumatic drug (DMARD) were enrolled. The primary efficacy endpoint was a 20% improvement in the American College of Rheumatology criteria (ACR20) in the fourth week. The occurrence of treatment-emergent adverse events (TEAEs) was the primary safety variable. Results: The highest percentage of TuNEX 25-mg- and 35-mg-treated patients achieved an ACR20 response (60% and 100%, respectively) for the first time at Week 2 during the 4-week treatment period. There was a strong trend toward a superior ACR20 response rate in the TuNEX 15-mg group (83.3%) in comparison with the TuNEX 25-mg group (40.0%) and the TuNEX 35-mg group (50.0%) at week 4. Patients who received 15-mg TuNEX, 25-mg TuNEX, and 35-mg TuNEX had 35.99%, 16.85%, and 21.86% reduction of disability indices of Health Assessment Questionnaire after drug treatment, respectively. The most commonly reported adverse event was injection-site reaction. The TEAEs were comparable between the three TuNEX-treated groups. Conclusion: TuNEX reduced the signs and symptoms of RA and improved physical function, with clinically acceptable safety and tolerability in patients who had previously received DMARDs. Copyright (C) 2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
引用
收藏
页码:544 / 551
页数:8
相关论文
共 50 条
  • [1] Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East
    Hammoudeh, Mohammed
    Adel, Al Awadhi
    Hasan, Eman Haji
    Akhlaghi, Maassoumeh
    Ahmadzadeh, Arman
    Abdollahi, Bahar Sadeghi
    [J]. INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2015, 2015
  • [2] A phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors
    Wang, Jing
    Huang, Yi
    Huang, Manping
    Deng, Jun
    Huang, Si
    Tian, Wenfang
    Liu, Hanchun
    Tang, Yan
    Cao, Bo
    Jiang, Lei
    Jiang, Xiaohui
    Zhao, Ke
    Yang, Runfeng
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Hou, Kexin
    Chen, Juan
    Tang, Yuan
    Zheng, Xiaohui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
    Patel, Manish R.
    Falchook, Gerald Steven
    Wang, Judy Sing-Zan
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Motlagh, Pejvack
    Miah, Kowser
    Mugundu, Ganesh M.
    Jones, Suzanne Fields
    Spigel, David R.
    Hamilton, Erika Paige
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts
    Bauer, Todd M.
    Moore, Kathleen
    Rader, Janet S.
    Simpkins, Fiona
    Mita, Alain
    Beck, J. Thaddeus
    Hart, Lowell
    Chu, Quincy
    Oza, Amit
    Tinker, Anna V.
    So, Karen
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh M.
    Jenkins, Suzanne
    Chmielecki, Juliann
    Jones, Suzanne
    Spigel, David R.
    Fu, Siqing
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [5] A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Wang, Judy Sing-Zan
    Falchook, Gerald Steven
    Charlton, Julie
    MacDonald, Alexander
    Strickland, Donald
    Jones, Suzanne Fields
    Pease, Elizabeth J.
    Brugger, Wolfram
    Burris, Howard A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] TARGET TRIAL: A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFICACY OF AZD4547 IN PATIENTS WITH RELAPSED/REFRACTORY FGFR FUSION POSITIVE GLIOMA
    Picca, Alberto
    Di Stefano, Anna Luisa
    Savatovsky, Julien
    Ducray, Francois
    Chinot, Olivier
    Moyal, Elisabeth Cohen-Jonathan
    Augereau, Paule
    Schmitt, Yohann
    Lerond, Julie
    Rousseaux, Nabila
    Fardeau, Christine
    Mokhtari, Karima
    Bielle, Franck
    Meyronet, David
    Iavarone, Antonio
    Sanson, Marc
    [J]. NEURO-ONCOLOGY, 2023, 25
  • [7] Efficacy and safety of OM-8980 in patients with rheumatoid arthritis: An open-label, long-term, multicenter study
    Bandilla, K
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1999, 60 (12): : 638 - 649
  • [8] TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma
    Picca, Alberto
    Di Stefano, Anna Luisa
    Savatovsky, Julien
    Ducray, Francois
    Chinot, Olivier
    Moyal, Elisabeth Cohen-Jonathan
    Augereau, Paule
    Le Rhun, Emilie
    Schmitt, Yohann
    Rousseaux, Nabila
    Yepnang, Ariane Murielle Mbekwe
    Estellat, Candice
    Charbonneau, Frederique
    Letourneur, Quentin
    Branger, Dominique Figarella
    Meyronet, David
    Fardeau, Christine
    Mokhtari, Karima
    Bielle, Franck
    Iavarone, Antonio
    Sanson, Marc
    [J]. NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [9] SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY
    Uchino, Keita
    Komoda, Masato
    Tomomatsu, Junichi
    Okamoto, Takahiro
    Horiuchi, Kiyomi
    Tsuji, Akihito
    Ito, Yasuhiro
    Todo, Takuya
    Rito, Ki
    Takahashi, Shunji
    [J]. ENDOCRINE PRACTICE, 2017, 23 (02) : 149 - 156
  • [10] OPEN-LABEL STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF FLUVASTATIN VERSUS BEZAFIBRATE FOR HYPERCHOLESTEROLEMIA
    FANGHANEL, G
    ESPINOSA, J
    OLIVARES, D
    SANCHEZ, L
    MORALES, M
    MARTINEZ, L
    MACIAS, G
    VALDES, E
    HERNANDEZ, G
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (02): : A57 - A61